文献速递免疫规划慢病防控与筛查

肥胖患者接受马狂犬病免疫球蛋白联合狂犬病疫苗接种暴露后预防的免疫原性反应

Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination.
PubMed 文献 · Vaccine · 2017-11-27

单中心、前瞻性、开放标签研究比较肥胖(BMI>30 kg/m2)与对照(BMI<25 kg/m2)的WHO III级狂犬病暴露患者在接受马狂犬病免疫球蛋白联合纯化鸡胚细胞狂犬病疫苗后的血清狂犬病毒中和抗体反应,结果显示两组抗体几何平均滴度无统计学显著差异,且未观察到速发型过敏反应和严重不良事件。

要点

  • 肥胖组与对照组在d7、d14、d28的狂犬病毒中和抗体GMT均无统计学显著差异。
  • 两组血清阳转率(RVNA≥0.5 IU/mL)在d7均为34%,d14和d28均为100%。
  • 研究期间未观察到速发型过敏反应和严重不良事件。

核心结论

  • 无证据表明肥胖患者抗体应答受到免疫抑制,马狂犬病免疫球蛋白联合狂犬病病毒疫苗接种用于暴露后治疗是安全的。

研究设计与样本

  • 单中心、前瞻性、开放标签研究,比较肥胖(BMI>30 kg/m2)与对照(BMI<25 kg/m2)的WHO III级狂犬病暴露患者。
  • 采用快速荧光灶抑制试验检测血清狂犬病毒中和抗体(RVNA)应答。
  • 所有患者接受马狂犬病免疫球蛋白联合纯化鸡胚细胞狂犬病疫苗暴露后预防。

主要发现

  • d7 RVNA GMT:肥胖组0.33(95%CI 0.23–0.46) vs 对照组0.39(95%CI 0.27–0.55)。
  • d14 RVNA GMT:肥胖组4.61(95%CI 3.20–6.63) vs 对照组3.78(95%CI 2.77–5.16)。
  • d28 RVNA GMT:肥胖组7.45(95%CI 5.86–9.49) vs 对照组5.93(95%CI 4.46–7.90)。
  • 两组RVNA GMT无统计学显著差异;血清阳转率(RVNA≥0.5 IU/mL)d7均为34%,d14和d28均为100%。
  • 研究期间未观察到速发型过敏反应和严重不良事件。

临床怎么用

  • 原文结论指出,马狂犬病免疫球蛋白联合狂犬病病毒疫苗用于暴露后治疗是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a risk factor for increased morbidity and mortality associated with many vaccine preventable infectious diseases such as influenza. Moreover, higher volume of passive rabies immunoglobulin (RIG) due to weight based dosing might suppress vaccine-induced immune responses in obese patients. This study aimed to evaluate the effect of obesity on humoral immune responses to combined equine RIG and rabies vaccine treatment among patients with WHO category III exposure to a rabies suspected animal. METHODS: A single centre, prospective, open-labelled study among WHO category III rabies exposed patients was conducted to compare serum rabies virus neutralizing antibody (RVNA) responses measured by rapid fluorescent focus inhibition test between obese (body mass index, BMI > 30 kg/m2) and control (BMI < 25 kg/m2) patients after combined immunization with equine rabies immunoglobulin and purified chick-embryo cell rabies vaccine for post exposure prophylaxis treatment. RESULTS: Post-vaccination geometric mean titer (GMT) of RVNA concentrations between two groups at day 7 were 0.33 (95% CI: 0.23, 0.46) vs 0.39 (95% CI: 0.27, 0.55), 4.61 (95% CI: 3.20, 6.63) vs 3.78 (95% CI: 2.77, 5.16) at day 14, and 7.45 (95% CI: 5.86, 9.49) vs 5.93 (95%CI: 4.46-7.90) at day 28 for obese and control patients, respectively. There was no statistically significant difference of RVNA GMT between two groups. Seroconversion to at least adequate concentration (RVNA titer ≥0.5 IU/mL) rates were 34% at day 7 and 100% at days 14 and 28 in both groups. There were no immediate hypersensitivity reaction and no serious adverse events observed during the study period. CONCLUSIONS: There was no evidence of immunosuppression of antibodies' responses in obese patients. Combined ERIG and rabies virus vaccination for post exposure treatment is safe.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sirikun J, Suputtamongkol Y, Rattanachinakorn P, et al. Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination. Vaccine. 2017. PMID: 29191737. doi:10.1016/j.vaccine.2017.11.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。